Nicotinamide Phosphoribosyl Transferase (Nampt) Is a Target of MicroRNA-26b in Colorectal Cancer Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhang, Chenpeng ^a,b   Tong, Jinlu ^c   Huang, Gang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DAPORINAD; MESSENGER RNA; MICRORNA; MICRORNA 26B; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; COLORECTAL NEOPLASMS; HCT116 CELLS; HT29 CELLS; HUMANS; MICRORNAS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84880844549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069963     Document Type: Article

References (47)

1. Garten A, Petzold S, Korner A, Imai S, Kiess W, (2009) Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20: 130-138.
2. Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, et al. (2012) Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. Eur J Pharmacol 674: 163-170.
3. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431-1437.
4. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430.
5. Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, et al. (1999) A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 463: 77-82.
6. Van BeijnumJR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, et al. (2002) Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127.
7. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, et al. (2010) Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 101: 1286-1291.
8. Srivastava M, Khurana P, Sugadev R, (2012) Lung Cancer Signature Biomarkers: tissue specific semantic similarity based clustering of Digital Differential Display (DDD) data. BMC Res Notes 5: 617.
9. Dalamaga M, (2012) Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses 79: 617-621.
10. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, et al. (2011) NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30: 907-921.
11. Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, et al. (2011) Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep 26: 1251-1257.
12. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, et al. (2012) Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 120: 3519-3529.
13. Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, et al. (2012) Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int J Cancer.
14. Esposito E, Impellizzeri D, Mazzon E, Fakhfouri G, Rahimian R, et al. (2012) The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation 9: 66.
15. Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, et al. (2012) Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun 424: 371-377.
16. Lai EC, (2002) Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364.
17. Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC, et al. (2012) MicroRNA Profiling in Lung Cancer Reveals New Molecular Markers for Diagnosis. Acta Cytol 56: 645-654.
18. Liu X, Chen Z, Yu J, Xia J, Zhou X (2009) MicroRNA profiling and head and neck cancer. Comp Funct Genomics: 837514.
19. Gennarino VA, Sardiello M, Avellino R, Meola N, Maselli V, et al. (2009) MicroRNA target prediction by expression analysis of host genes. Genome Res 19: 481-490.
20. Sarver AL, Li L, Subramanian S, (2010) MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 70: 9570-9580.
21. He X, Dong Y, Wu CW, Zhao Z, Ng SS, et al. (2012) MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1. Mol Med.
22. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, et al. (2012) MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40: 761-774.
23. Hasmann M, Schemainda I, (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442.
24. Khan JA, Tao X, Tong L, (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13: 582-588.
25. Bi TQ, Che XM, (2010) Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 10: 119-125.
26. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443.
27. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, et al. (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 11: 313-321.
28. Drevs J, Loser R, Rattel B, Esser N, (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23: 4853-4858.
29. Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, et al. (2009) APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 113: 6035-6037; author reply 6037-6038.
30. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, et al. (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113: 3276-3286.
31. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14: 2588-2592.
32. Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, et al. (2011) MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett 585: 1363-1367.
33. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, et al. (2011) Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2: 669-683.
34. Zhao L, Sun Y, Hou Y, Peng Q, Wang L, et al. (2012) MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer. Int J Biochem Cell Biol 44: 2051-2059.
35. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
36. Ji Y, He Y, Liu L, Zhong X, (2010) MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett 584: 961-967.
37. Gao W, Shen H, Liu L, Xu J, Shu Y, (2011) MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 137: 557-566.
38. Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, et al. (2011) Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med 15: 1941-1954.
39. Chen YQ, Wang XX, Yao XM, Zhang DL, Yang XF, et al. (2012) Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. J Nephrol 25: 566-576.
40. Wu N, Zhao X, Liu M, Liu H, Yao W, et al. (2011) Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 6: e16264.
41. Zhang Z, Florez S, Gutierrez-Hartmann A, Martin JF, Amendt BA, (2010) MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem 285: 34718-34728.
42. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, et al. (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40: 4615-4625.
43. Chen XY, Zhang HS, Wu TC, Sang WW, Ruan Z (2012) Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation. Int J Biochem Cell Biol.
44. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
45. Adya R, Tan BK, Punn A, Chen J, Randeva HS, (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78: 356-365.
46. Kim JY, Bae YH, Bae MK, Kim SR, Park HJ, et al. (2009) Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta 1793: 1759-1767.
47. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, et al. (2008) Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283: 34833-34843.